While in neuroblastoma the presence of an MYCN amplification clearly discriminates tumor subtypes [34], neuroblastoma CR TFs depend on BET bromodomains [35], and MYCN-amplified neuroblastomas respond better to BET bromodomain inhibition [36], we did not see any difference among FP-RMS models with or without MYCN amplification. This evidence concerns the gene MYCN and neoplasm.